Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

The patients will be treated with systemic FOLFIRINOX chemotherapy of adjusted dosage.

Inclusion criteria

• Patients should be voluntary to the trial and provide with signed informed consent.
• Histologically confirmed diagnosis of pancreatic cancer
• Male or female, Age: 18-79 years old.
• No recurrence or metastasis was observed from a follow-up of 4 to 8 weeks by CT scan after radical surgery.
• the value of Carbohydrate Antigen19-9(CA19-9) < 180U/mL within 12 weeks after surgery.
• No previous chemotherapy
• Eastern Cooperative Oncology Group(ECOG) performance status of 0-1
• normal function of organ system including the followings.

• No hematologic dysfunction(Platelets ≥90×10^9/L; Neutrophil ≥2×109/L;Hemoglobin ≥90g/L).
• Serum bilirubin ≤ 1.2 × upper limits of normal(ULN); aminotransferase ≤ 5 × ULN.
• Serum creatinine ≤ 1.25× ULN, or creatinine clearance rate(CCR) ≥60mL/min(calculated by Cockcroft-Gault formula).
• ECOG scored as 0-1.
• Life expectancy > 3 months.

Exclusion criteria

• Patient is concurrently using other antineoplastic agent.
• Known severe hypersensitivity to drugs in the regimen.
• Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment(with the exception of nonmelanoma skin cancer or cervical carcinoma in situ).
• Evidence of serious heart disease, including recorded history of congestive heart-failure, uncontrolled serious arrhythmia, angina that needs treatment of drugs, clinical diagnosed cardiac valve disease, history of serious myocardial infarction and intractable hypertension.
• Evidence of chronic diarrhea(≥4 times/day) or renal dysfunction.
• Evidence of active infection or active epidemic disease.
• Psychiatric illness that would prevent the patient from giving informed consent
• Pregnant or lactating women.